CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
CRISPR Therapeutics's pe ratio was 20.4× on Jul 29, 2022, against 199.6× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Jul 29, 2022 | 20.4× | +4.5 |
| 2021 | Dec 31, 2021 | 15.9× | −183.7 |
| 2020 | Oct 30, 2020 | 199.6× | – |
See a number that looks wrong?